The problem for both patients and doctors is that the early symptoms are difficult to distinguish from less dangerous infections such as a severe flu or winter vomiting disease. A researcher at Lund University in Sweden has now discovered a substance in the blood which shows both whether a patient has sepsis and how serious the case is.
“Approximately one in five patients with sepsis who are admitted to hospital are at risk of developing severe sepsis within the first 24 hours. If the doctor doesn’t immediately understand that the patient is seriously ill, the risk is that he or she does not receive adequate treatment. The patient could also end up on a ward with lower staffing levels and thus less close supervision”, says doctor and researcher Adam Linder.
In sepsis (formerly called blood poisoning), the immune system overreacts to an infection, which triggers a series of events in the body. Among other things, the blood vessels begin to leak, resulting in a fall in blood pressure that eventually damages the kidneys, heart and brain. Sepsis is the tenth most common cause of death in the world, and the most common cause of death among already weak patients in hospital intensive care units.
Sepsis is treated with antibiotics, fluids and oxygen. But first, the patients must be diagnosed with sepsis, yet the markers used do not always give a correct diagnosis. Adam Linder has found a better biomarker in protein HBP (heparin-binding protein). This is released by a certain type of white blood cell in amounts which correspond to the immune system’s reaction: the greater the overreaction – and thus the risk of sepsis – the greater the amount of HBP in the blood of a patient.
Measurements of HBP can also be used in connection with meningitis. There are two forms of the disease, bacterial meningitis and viral meningitis. Again, it is important to get a quick and accurate diagnosis in order to reduce the risk of complications and death. The amount of HBP in a patient’s spinal fluid has been shown to provide a more accurate diagnosis than the methods currently used.
However, for HBP measurements to be used successfully in hospitals it must be possible to perform the analysis quickly.
“I analysed my samples in the lab, which took six hours. A doctor in an accident and emergency department cannot wait that long. The time must be reduced to no more than one hour”, says Adam Linder.
Hansa Medical, a company in Lund, is currently developing patented methods to quickly analyse HBP in connection with both meningitis and sepsis.
Adam Linder presented his thesis on HBP on 13 May. The title of the thesis is Studies on heparin binding protein in bacterial infections.
Adam Linder can be contacted by telephone, +46 46 17 13 09 or +46 709 280233, or by email, firstname.lastname@example.org.
Ingela Björck | idw
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy